New Study Aims to Reduce Recurrence Risk for Select Patients
Dr. Kim A. Reiss is leading a study of the PARP inhibitor olaparib to delay or prevent a recurrence of surgically removed pancreatic cancer.
Testing a PARP Inhibitor for Metastatic Pancreatic Cancer Patients with DNA Repair Mutations
Researchers are testing a PARP inhibitor that is effective for cancers in pancreatic cancer patients with DNA repair mutations.
Finding More Clues about Circulating Tumor DNA
Researcher Dr. Gehan Botrus looks at circulating tumor DNA for genetic information on a patient’s pancreatic cancer to personalize treatment.
CRISPR-Engineered Immunotherapy for Metastatic GI Tract Cancers
CRISPR technology is used as part of an immunotherapy clinical trial for metastatic pancreatic cancer and other GI cancers.
PARP Inhibitor as Maintenance for Pancreatic Cancer Patients with BRCA1, BRCA2, or PALB2 Mutations
A new clinical trial tests a PARP inhibitor as maintenance treatment for pancreatic cancer patients with BRCA1/2 or PALB2 mutations.
Chemotherapy Plus Stem Cell Infusion and Vitamins for BRCA Mutated Pancreatic Cancer
A clinical trial for pancreatic cancer patients with a BRCA mutation uses a combination of chemotherapy, vitamins, and stem cells.
RNA Precision Trial for Pancreatic Cancer Opens At Columbia
Dr. Andrea Califano leads a precision oncology clinical trial of the OncoTreat platform, which looks at proteins to determine treatment.
A Year in Review: 2020
Although COVID-19 dominated the news, important new research and clinical trials began for pancreatic cancer patients.
PATHFINDER Blood Test Trial Focused on Early Detection
Dr. Minetta Liu is part of the team conducting a clinical trial to find biomarkers that will become an easy blood test for pancreatic cancer.
Tumor Biology Matters
Dr. Lynn Matrisian of PanCAN, explains that molecular profiling of a pancreatic cancer patient’s tumor can show which treatment will work best.